327 related articles for article (PubMed ID: 16784247)
1. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist.
Corcóstegui R; Labeaga L; Innerárity A; Berisa A; Orjales A
Drugs R D; 2006; 7(4):219-31. PubMed ID: 16784247
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity.
Corcóstegui R; Labeaga L; Innerárity A; Berisa A; Orjales A
Drugs R D; 2005; 6(6):371-84. PubMed ID: 16274260
[TBL] [Abstract][Full Text] [Related]
3. Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions.
Gutiérrez B; Dordal A; Fort M; Galicia J; Farré AJ
Methods Find Exp Clin Pharmacol; 1996; 18(6):397-406. PubMed ID: 8892269
[TBL] [Abstract][Full Text] [Related]
4. Anti-anaphylactic activity of the novel selective histamine H1 receptor antagonist mizolastine in the rodent.
Levrier J; Duval D; Prouteau M; Voltz C; Berry CN; Lloyd KG; Scatton B
Arzneimittelforschung; 1995 May; 45(5):559-68. PubMed ID: 7541995
[TBL] [Abstract][Full Text] [Related]
5. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H
Bosma R; van den Bor J; Vischer HF; Labeaga L; Leurs R
Eur J Pharmacol; 2018 Nov; 838():107-111. PubMed ID: 30201377
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.
Kreutner W; Hey JA; Anthes J; Barnett A; Young S; Tozzi S
Arzneimittelforschung; 2000 Apr; 50(4):345-52. PubMed ID: 10800633
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study.
Kuna P; Bachert C; Nowacki Z; van Cauwenberge P; Agache I; Fouquert L; Roger A; Sologuren A; Valiente R;
Clin Exp Allergy; 2009 Sep; 39(9):1338-47. PubMed ID: 19438584
[TBL] [Abstract][Full Text] [Related]
8. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects.
Grant JA; Riethuisen JM; Moulaert B; DeVos C
Ann Allergy Asthma Immunol; 2002 Feb; 88(2):190-7. PubMed ID: 11868924
[TBL] [Abstract][Full Text] [Related]
9. Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor.
Kakiuchi M; Ohashi T; Musoh K; Kawamura K; Morikawa K; Kato H
Jpn J Pharmacol; 1997 Apr; 73(4):291-8. PubMed ID: 9165365
[TBL] [Abstract][Full Text] [Related]
10. Comparative antiallergic effects of second-generation H1-antihistamines ebastine, cetirizine and loratadine in preclinical models.
Llupià J; Gras J; Llenas J
Arzneimittelforschung; 2003; 53(2):93-7. PubMed ID: 12642964
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
[TBL] [Abstract][Full Text] [Related]
12. Bilastine for the relief of allergy symptoms.
Sádaba Díaz de Rada B; Azanza Perea JR; Gomez-Guiu Hormigos A
Drugs Today (Barc); 2011 Apr; 47(4):251-62. PubMed ID: 21573249
[TBL] [Abstract][Full Text] [Related]
13. Bilastine as a potential treatment in allergic rhinitis.
Kowal K; DuBuske L
Am J Rhinol Allergy; 2014; 28(4):312-6. PubMed ID: 25197918
[TBL] [Abstract][Full Text] [Related]
14. Antiallergic effects of H1-receptor antagonists.
Baroody FM; Naclerio RM
Allergy; 2000; 55 Suppl 64():17-27. PubMed ID: 11291777
[TBL] [Abstract][Full Text] [Related]
15. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber.
Horak F; Zieglmayer P; Zieglmayer R; Lemell P
Inflamm Res; 2010 May; 59(5):391-8. PubMed ID: 19943178
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects.
Matsushita N; Aritake K; Takada A; Hizue M; Hayashi K; Mitsui K; Hayashi M; Hirotsu I; Kimura Y; Tani T; Nakajima H
Jpn J Pharmacol; 1998 Sep; 78(1):11-22. PubMed ID: 9804057
[TBL] [Abstract][Full Text] [Related]
17. Preclinical comparison of ebastine and other second generation H1-antihistamines.
Yakuo I; Yabuuchi M; Ito T
Pharmacol Toxicol; 2001 Oct; 89(4):171-6. PubMed ID: 11881966
[TBL] [Abstract][Full Text] [Related]
18. Comparative inhibition by bilastine and cetirizine of histamine-induced wheal and flare responses in humans.
Church MK
Inflamm Res; 2011 Dec; 60(12):1107-12. PubMed ID: 21874559
[TBL] [Abstract][Full Text] [Related]
19. Antiallergic effect of ZCR-2060: antihistaminic action.
Abe T; Omata T; Yoshida K; Matsumura T; Ikeda Y; Segawa Y; Matsuda K; Nagai H
Jpn J Pharmacol; 1994 Sep; 66(1):87-94. PubMed ID: 7861672
[TBL] [Abstract][Full Text] [Related]
20. Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80.
McLeod RL; Mingo GG; Kreutner W; Hey JA
Life Sci; 2005 Mar; 76(16):1787-94. PubMed ID: 15698856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
